Healthcare Marketplace Update

The federally run Health Insurance Marketplace officially opens on October 1st.  This will be the first day that consumers can examine the plans offered in Ohio.  Plans must be chosen by December 15 to begin coverage on January 1st, with delayed enrollment to those who choose their plans after the deadline.  Before October 1st, OAC encourages everyone to create an account at healthcare.gov and familiarize themselves with the user-friendly site.  After October 1st, individuals should begin exploring the plans that may suit their needs.  Soon we will provide tools to assess the relevance of each plan to an individual’s needs and will work with Marketplace Navigators, Case Managers, and HIV care providers to answer any questions concerning people living with HIV/AIDS.  Plans have not yet been identified or analyzed that may offer people living with HIV/AIDS the most comprehensive or specialized care, nor will we directly recommend any plan over another; it is up to the individual consumer to make his/her choice.  The Ohio AIDS Coalition recommends to those who qualify or think they may qualify for insurance in the Health Marketplace to take their time and examine every plan that might meet their needs.  For resources on understanding Healthcare Reform and the Health Insurance Marketplace, check out our Community Resources page.

1V0-601 Exam   ,
300-209   ,
100-101 dumps   ,
N10-006 Study Guides   ,
3002 dumps   ,
640-911 certification   ,
OG0-093 dumps   ,
210-260 dumps   ,
c2010-657 dumps   ,
200-355 certification   ,
350-050 Exam   ,
700-501 Exam   ,
70-532 certification   ,
PR000041 pdf   ,
1z0-808 Study Guides   ,
9L0-012   ,
3002   ,
ICGB Study Guides   ,
640-916 pdf   ,
EX200 Exam   ,
PEGACPBA71V1 dumps   ,
070-461 test   ,
MB2-704 Study Guides   ,
70-270 pdf   ,
101 dumps   ,
300-135   ,
200-355 pdf   ,
NS0-157 Exams   ,
70-413 exam   ,
ICGB certification   ,
ICGB Study Guides   ,
LX0-104 certification   ,
EX200 dumps   ,
350-050 test   ,
1Z0-061 dumps   ,
200-120 pdf   ,
PMP Brain dumps   ,
LX0-104 exam   ,
CISSP dumps   ,
3002 Exam   ,
9A0-385   ,
1Z0-060   ,
70-533 Test   ,
MB2-704 certification   ,
OG0-093 Exam   ,
70-246 exam   ,
200-120   ,
1Z0-804 Brain dumps   ,
000-105   ,
CRISC test   ,
220-901 certification   ,
NS0-157   ,
300-075 Exam   ,
200-310 certification   ,
1Z0-144 test   ,
CAP Exam   ,
300-070 Test   ,
2V0-620 dumps   ,
MB2-707 test   ,
220-801 exam   ,
101-400 Exam   ,
CISSP pdf   ,
CCA-500 certification   ,
640-911 Study Guides   ,
70-246 dumps   ,
70-270 test   ,

New HIV Vaccine Proves Successful In Phase 1 Human Trial

By 

A vaccine for human immunodeficiency virus (HIV) has proved successful in a Phase 1 clinical trial with no adverse effects in human patients, Sumagen Canada Inc. and Western University of Ontario announced today. The vaccine, which was developed by Dr. Chil-Yong Kang and his team, is the first genetically modified, whole-killed vaccine to be approved for testing in humans.

“We are now prepared to take the next steps towards Phase 2 and Phase 3 clinical trials,” stated Jung-Gee Cho, the CEO of Sumagen Co. Ltd., in a press release. “We are opening the gate to pharmaceutical companies, government, and charity organization for collaboration to be one step closer to the first commercialized HIV vaccine.”

Human Testing

The clinical trial, which evaluated safety, tolerability, and immune responses, was initiated in March 2012 and completed in August 2013. The study of the vaccine, known as SAV001-H, followed intramuscular administration in HIV-infected, asymptomatic men and women, 18 to 50 years of age. The trial studied the vaccine’s effects on volunteers as compared to a placebo group.

After receiving the vaccination, volunteers visited test sites on weeks four, six, 12, 18, 26, and 52 for a general physical examination as well as analysis of clinical chemistry, hematology, and urinalysis. Researchers observed no serious adverse events and also found a surprising boost in antibody production, which may forecast success in Phase 2 trials measuring immune response.

The antibody against p24 capsid antigen increased as much as 64-fold in some vaccinees while the antibody against gp120 surface antigen increased up to eight-fold. P24 is a structural protein that makes up most of the HIV viral core also known as the ‘capsid.’ High levels of p24 are present in the blood serum of newly infected individuals during the short period between infection and seroconversion, making p24 antigen assays useful in diagnosing primary HIV infection. A glycoprotein, gp120, is necessary for attachment to cell surface receptors and also allows for the HIV virus to enter cells.

Production

SAV001-H, which was produced at a manufacturing facility in the U.S., is the only HIV vaccine developed in Canada and one of only a few in the world. Sumagen anticipates having the first HIV vaccine approved for market. HIV currently affects more than 34 million people who live with the virus worldwide, according to the World Health Organization. Over the past three decades, HIV has claimed more than 25 million lives.

Since the virus was characterized in 1983, pharmaceutical companies and academic institutions around the world have attempted, yet consistently failed, to develop a vaccine. What is unique about Kang’s vaccine is its use of a killed-whole HIV-1, which is similar to the vaccines developed for polio, influenza, and rabies. HIV-1 is also genetically engineered; this raises its safety profile and the possibility of it being produced in large quantities.

Sumagen is a member of Curo Group, a Seoul-based company with subsidiaries or affiliates in financial services, information technology, and other business areas. Sumagen has secured patents for the SAV001 vaccine in more than 70 countries, including the U.S., the European Union, China, India, and South Korea.

Development of Sumagen’s HIV vaccine has been supported by the government of Canada as well as the Bill and Melinda Gates Foundation.

(taken from Medical Daily)